Skip to content

Transcutaneous Mechanical Nerve Stimulation in the Treatment of Incontinence

Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Stress Incontinence and Urge Incontinence

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01366066
Enrollment
4
Registered
2011-06-03
Start date
2011-05-31
Completion date
2013-06-30
Last updated
2013-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence, Urge Urinary Incontinence

Keywords

Stress incontinence, urge incontinence, overactive bladder syndrome, vibration, nerve stimulation

Brief summary

During transcutaneous mechanical nerve stimulation in spinal cord injured men an increase in pressure was observed in the external urethral sphincter along with an increase in bladder capacity. In a subsequent study it was demonstrated that Transcutaneous Mechanical Nerve Stimulation (TMNS) in women could induce pressure increment of the external urethral sphincter. A pilot study have since shown that after 6 weeks of stimulation 24 out of 33 women suffering from urinary stress incontinence were able to contract their pelvic floor muscles and had become free of symptoms. Another pilot study has shown promising effect on the overactive bladder syndrome. The present study aims to treat urinary incontinence and includes 2 groups of patients with 30 patients in each group: Women suffering from urinary stress incontinence and women suffering from urge incontinence. A medical vibrator is used and in each group the subjects will be randomized to vibration treatment or no vibration treatment. All patients will receive pelvic floor training and all women suffering from urge incontinence will receive anticholinergic medications. The stimulation will be performed at the perineum every day for 6 weeks with an amplitude of 2 mm and a frequency of 100 Hz. Results will be evaluated on the basis of questionnaires, micturition diaries and diaper tests. If the investigators are able to demonstrate a significant reduction in the incontinence symptoms in the subjects the investigators asses that vibration can be a way of reestablishing a normal function of the pelvic floor muscles and bladder function in incontinent patients.

Interventions

DEVICETranscutaneous mechanical nerve stimulation

A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks.

Sponsors

Zealand University Hospital
CollaboratorOTHER
Copenhagen University Hospital at Herlev
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women suffering from stress incontinence OR Women suffering from urge incontinence /overactive bladder syndrome * Ongoing anticholinergic treatment in the urge incontinence/overactive bladder syndrome group * Patient capable of understanding protocol and performing treatment

Exclusion criteria

* On going pregnancy or breast feeding * Treatment with anticholinergic medications in the stress incontinence group * Treatment with diuretic drugs * Acute illness (including infection, trauma and haematuria) * Fibromyalgia * Faecal incontinence * Known neurological disease * Bladder pain syndrome * Genital prolaps \> stage 2 on the Pelvic Organ Prolapse Quantification System POP-Q * Previous treatment with neuromodulation or Botox * Previous pelvic floor surgery or radiation

Design outcomes

Primary

MeasureTime frame
Diaper test - weight (grams)Assesment at baseline and again after 6 weeks of treatment (when treatment is terminated)

Secondary

MeasureTime frame
Validated symptom score (ICI-Q) including: changes in incontinence and micturition patterns; patients' subjective assessment of their symptomsAssesment at baseline and again after 6 weeks of treatment (when treatment is terminated)
Treatment satisfactionAfter 6 weeks of treatment (when treatment is terminated)
Urethral pressure (in the stress group)Assesment at baseline and again after 6 weeks of treatment (when treatment is terminated)
Episodes of over active bladder during urodynamics (urge patients)Assesment at baseline and again after 6 weeks of treatment (when treatment is terminated)
Micturition diary - The number of involuntary incontinence and normal micturition episodesAssesment at baseline and again after 6 weeks of treatment (when treatment is terminated)

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026